Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-Dose vs Conventional-Dose Radiotherapy in Stage II Nasopharyngeal Carcinoma Under Immunotherapy
NCT07328854Phase 3Recruiting
- Start
- Nov 2025
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in nasopharyngeal carcinoma (NPC) (2 arms). Primary endpoints: Progression-Free Survival at 3 years and Incidence of >=3 grade adverse events at 3 years. Started Nov 2025; status: recruiting.
02
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07328854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328854.